Claims

[Claim 1]

Use of a polysaccharide selected from a polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan, inulin and xylo-oligosaccharide, or a salt thereof, in the manufacture of a pharmaceutical composition for reducing nasal polyps.

[Claim 2]

The use according to claim 1, wherein the polysaccharide is selected from a polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan and inulin.

[Claim 3]

The use according to claim 1 or 2, wherein the pharmaceutical composition is to be administered intranasally.

[Claim 4]

Use of a polysaccharide selected from a polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan, inulin and xylo-oligosaccharide, or a salt thereof, in the manufacture of a pharmaceutical composition for reducing nasal polyps in a patient with chronic sinusitis.

[Claim 5]

The use according to claim 4, wherein the polysaccharide is selected from a polysulfated chondroitin sulfate, chondroitin sulfate, keratan sulfate,

heparan sulfate, dextran sulfate, pentosan polysulfate, chondroitin, glucomannan and inulin.

[Claim 6]

The use according to claim 4 or 5, wherein the patient with chronic sinusitis is a patient with eosinophilic sinusitis or non-eosinophilic sinusitis.

[Claim 7]

The use according to any one of claims 4 to 6, wherein the patient with chronic sinusitis is a patient with eosinophilic sinusitis.

[Claim 8]

The use according to any one of claims 4 to 7, wherein the pharmaceutical composition is an intranasal formulation.